Cite
HARVARD Citation
Mok, T. et al. (2016). Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer. Lung cancer. pp. 1-8. [Online].